Compare PWP & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PWP | NTLA |
|---|---|---|
| Founded | 2006 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.6B |
| IPO Year | 2020 | 2016 |
| Metric | PWP | NTLA |
|---|---|---|
| Price | $21.69 | $14.11 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 20 |
| Target Price | ★ $23.50 | $20.45 |
| AVG Volume (30 Days) | 753.5K | ★ 2.9M |
| Earning Date | 05-01-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.29% | N/A |
| EPS Growth | ★ 138.52 | 27.43 |
| EPS | ★ 0.47 | N/A |
| Revenue | N/A | ★ $67,671,000.00 |
| Revenue This Year | $31.87 | N/A |
| Revenue Next Year | $16.54 | $62.75 |
| P/E Ratio | $45.87 | ★ N/A |
| Revenue Growth | N/A | ★ 16.92 |
| 52 Week Low | $14.99 | $6.83 |
| 52 Week High | $25.93 | $28.24 |
| Indicator | PWP | NTLA |
|---|---|---|
| Relative Strength Index (RSI) | 74.15 | 54.80 |
| Support Level | $20.70 | $10.44 |
| Resistance Level | $23.01 | $14.32 |
| Average True Range (ATR) | 0.80 | 0.82 |
| MACD | 0.51 | 0.15 |
| Stochastic Oscillator | 95.18 | 67.99 |
Perella Weinberg Partners is an independent advisory firm that provides strategic and financial advice to a wide range of clients. The Company's activities as an investment banking advisory firm constitute a single business segment that provides a range of advisory services, including advice related to strategic and financial decisions, mergers and acquisitions execution, shareholder and defense advisory, financing and capital solutions advice with resources focused on restructuring and liability management, capital markets advisory, private capital placement, as well as specialized underwriting and research services for the energy and related industries.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.